Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients

Yonsei Medical Journal

Volumn 50, Issue 4, 2009, Pages 517-520

  Hong, Ji Man ^a   Choi, Young Chul ^a   Kim, Won Joo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Epilepsy; Hypoalbuminemia; Phenytoin

Indexed keywords

ALBUMIN; PHENYTOIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; ENVIRONMENTAL FACTOR; EPILEPSY; FEMALE; HEREDITY; HUMAN; HYPOALBUMINEMIA; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; YOUNG ADULT;

EID: 70449726947     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2009.50.4.517     Document Type: Article

References (22)

1. Nuwer MR, Browne TR, Dodson WE, Dreifuss FE, Engel J Jr, Leppik IE, et al. Generic substitutions for antiepileptic drugs. Neurology 1990;40:1647-1651
2. Richens A, Dunlop A. Serum-phenytoin levels in management of epilepsy. Lancet 1975;2:247-248
3. Kilpatrick CJ, Wanwimolruk S, Wing LM. Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmacol 1984;17:539-546 (Pubitemid 14057460)
4. Mackichan JJ. Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet 1984;9 Suppl 1:32-41.
5. Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med 1999;123:822-823
6. Perucca E. Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies. Clin Pharmacokinet 1984;9 Suppl 1:71-78
7. Bryson SM, Al-Lanqawi Y, Kelman AW, Whiting B. Comparison of a Bayesian forecasting technique with a new method for estimating phenytoin dose requirements. Ther Drug Monit 1988; 10:80-84 (Pubitemid 18053630)
8. Levine M, Chang T. Therapeutic drug monitoring of phenytoin. Rationale and current status. Clin Pharmacokinet 1990;19:341-358
9. Bailey DN, Briggs JR. The binding of selected therapeutic drugs to human serum alpha-1 acid glycoprotein and to human serum albumin in vitro. Ther Drug Monit 2004;26:40-43 (Pubitemid 38140909)
10. Fedler C, Stewart MJ. Plasma total phenytoin: a possibly misleading test in developing countries. Ther Drug Monit 1999;21: 155-160 (Pubitemid 29168891)
11. Sheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morelli HF, editors. Clinical Pharmacology: Basic Principles in Therapeutics. New York: Macmillan; 1978. p.71-109.
12. Mlynarek ME, Peterson EL, Zarowitz BJ. Predicting unbound phenytoin concentrations in the critically ill neurosurgical patient. Ann Pharmacother 1996;30:219-223 (Pubitemid 26088293)
13. Dutkiewicz G, Wójcicki J, Gawrońska-Szklarz B. [The influence of hyperlipidemia on pharmacokinetics of free phenytoin.] Neurol Neurochir Pol 1995;29:203-211
14. Dasgupta A, Crossey MJ. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. Am J Med Sci 1997;313:75-79 (Pubitemid 27089857)
15. Doucet J, Fresel J, Hue G, Moore N. Protein binding of digitoxin, valproate and phenytoin in sera from diabetics. Eur J Clin Pharmacol 1993;45:577-579 (Pubitemid 24036939)
16. Hooper WD, Bochner F, Eadie MJ, Tyrer JH. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 1974;15:276-282
17. Odar-Cederlöf I, Borga O. Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. Eur J Clin Pharmacol 1974;7:31-37
18. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002; 24:379-385
19. Peterson GM, Khoo BH, von Witt RJ. Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit 1991;13:415-419
20. Lindow J, Wijdicks EF. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994;105:602-604 (Pubitemid 24066744)
21. Wolf GK, McClain CD, Zurakowski D, Dodson B, McManus ML. Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. Pediatr Crit Care Med 2006;7:434-439 (Pubitemid 44386068)
22. Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL. Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation. Ther Drug Monit 2001;23:263-267